https://www.selleckchem.com/pr....oducts/tinlorafenib.
The number of facilities able to show that they met specific benchmarks increased with length of participation for many but not all measures. Trends toward meeting more benchmarks were apparent for cancer detection, timely imaging, not lost at biopsy, known minimal status (P .01 for all), and proportion of screening-detected cancers that were minimal and early stage (P .001 for both). Participation in the quality improvement program seemed to lead to improvements in patient tracking, callback and detection, and timeliness
Like
Comment
Share
